SAN DIEGO, CA (MARKET WIRE) Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Michael R. Hufford, PhD, its Vice President of Corporate Development, will participate in Citi's Biotech Day on September 8, 2008.

[NEWS] Data are Consistent With Previously announced Interim Findings BIRMINGHAM, Ala., Sept. 4 /PRNewswire-FirstCall/ — BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of safety and to…

[NEWS] SYDNEY, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall/ — Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers. The Phase 3 trial is being conducted in 41 hospitals across North America, Argentina and Germany, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the United States. …

The world?s largest biotechnology organization isn?t endorsing a candidate for president. But when that next U.S. leader is elected, the Biotechnology Industry Organization?s members will call on him to significantly increase the federal Food and Drug Administration?s budget, so it can speed up the review process for cutting-edge medicines now waiting in the pipeline for approval.

SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) today reported that an equity award was made to one new employee. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of equity awards to new employees. In accordance with Nasdaq rules, this grant was made under an equity incentive plan without stockholder approval. Nasdaq rules require a public announcement of equity awards to be made under this type of plan. One employee was

CALGARY, ALBERTA (MARKET WIRE) Stem Cell Therapeutics Corp.(TSX VENTURE: SSS) ("SCT") has received results from the Data Safety Monitoring Board (DSMB) that provides oversight for the Company's Phase IIb REGENESIS trial. The DSMB has completed a safety analysis and has recommended the trial continue as per the protocol.

GREENSBORO — N.C. A&T State university is one of a select group of universities nationwide, and the first historically black institution ever, chosen to lead a prestigious National science Foundation Engineering Research Center.

LONDON, UNITED KINGDOM (MARKET WIRE) Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.

MIAMI, FL (MARKET WIRE) OncoMune LLC, a biotechnology company focused on developing targeted cancer therapeutics, announced the publication of its preclinical OCM-8054 data. The publication entitled, "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS," appeared in the May 23rd 2008 issue of the scientific journal, Biochemical and Biophysical Research Communications, Volume 370, Issue 1, Pages 109-112.

Southern Research Institute has received a $14.7 million National Institutes of Health grant to become a production site for a national collaborative research network designed to expedite drug development.